ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced it has entered into securities purchase agreements with healthcare focused institutional investors along-side significant participation from an entity affiliated with the Chairman of the Company’s Board of Direct
Scientists studying Alzheimer's disease (AD) have identified thousands of genetic variants in the genome in the development of this progressive neurodegenerative disease.